20.3 Site Readiness and Activity-Specific Release
Key Takeaways
Sponsor release labels are internal processes rather than universal regulatory definitions.
Shipment, screening, enrolment and dosing can have different prerequisites.
Critical readiness evidence must be verified before dependent activities.
Site Readiness and Activity-Specific Release
Note
Study Start-Up represents the critical operational bridge connecting site selection to active participant enrollment. The sponsor and monitor verify the relevant permissions, agreements, qualifications and operational readiness before each dependent activity. Shipment, training, screening, enrolment and dosing can have different prerequisites; apply the actual framework and documented release process.
In clinical research operations, initiating a site before it is genuinely prepared is a risk for protocol noncompliance and avoidable participant or data problems. The Site Initiation Visit (SIV) is not an informal meet-and-greet; it is a documented readiness and training activity where the investigative team is thoroughly educated on protocol requirements, drug safety reporting, investigational product handling, and Good Clinical Practice.
Coordinating start-up activities requires meticulous attention to essential documents, cross-departmental alignment, and absolute adherence to the sponsor's "Regulatory Green Light" process.
The Study Start-Up Continuum & The "Regulatory Green Light"
The Regulatory Green Light (also known as Authorization to Ship or Authorization to Enroll) is the formal quality gate maintained by the sponsor's clinical quality assurance and regulatory affairs teams. It ensures that an investigative site has met the relevant readiness conditions across coordinated operational tracks:
The sponsor readiness gate
Follow the documented sponsor process and applicable prerequisites for each activity. Regulatory/ethics staff may verify the required decisions and agreements; operations confirms relevant qualification, training and readiness; supply functions release product under the appropriate conditions. The exact participants, sign-offs and names of gates depend on the trial and organisation. A particular US investigator form is not an international ICH requirement.
A sponsor’s internal authorisation does not replace required ethics or authority permission. Likewise, receiving an approval letter does not establish that staff, facilities, product and systems are ready. Document what the site is allowed to do, any restrictions and the evidence supporting the release. The monitor should not use one universal checklist to authorise activities whose prerequisites differ.
An unresolved critical safety or access problem should be addressed before the dependent activity. Lower-impact tasks can be managed according to an authorised plan when appropriate. Avoid claiming that every action item, however minor, always prohibits every activity; assess the actual requirement and risk. Keep decisions traceable so the site can distinguish permission to screen, enrol, dispense and dose.
Readiness evidence before affected activities
Use E6(R3) Appendix C and the trial's activation process. Verify current protocol and agreements, required ethics/authority decisions, approved participant materials, relevant IB/product instructions, qualifications, training, appropriate laboratory/technical evidence, product arrangements and fit-for-purpose systems. Some records apply only when relevant; a universal FDA 1572 package is not an international requirement.
| Readiness area | Evidence to examine | Consequence of a gap |
|---|---|---|
| Ethics and authorisation | Correct documents and versions covered by a valid decision | Do not begin activities lacking required approval |
| People and training | Qualified staff, investigator oversight and task preparation | Complete required preparation before the task |
| Product and facilities | Appropriate storage, accountability, supplies and contingency | Resolve risks before release/use of affected product |
| Laboratory/diagnostics | Suitable methods, reference ranges and required quality evidence | Do not rely on unverified critical assessments |
| Systems and source access | Attributable access, training and agreed records | Resolve access/data risks before dependent activities |
| Financial/operational agreements | Clear responsibilities, payments and injury arrangements | Resolve conditions required by the agreement and activation plan |
A conditional opinion requiring substantive changes is not final approval to begin. Likewise, a sponsor's internal release label is not itself regulatory approval. Establish the specific permission needed for each activity. Product shipment, site training and enrolment can have different prerequisites under the actual framework and sponsor procedure.
Preparing for and Conducting the Site Initiation Visit (SIV)
The Site Initiation Visit is conducted after essential documents are in place and IRB approval has been granted, either immediately prior to or upon receipt of investigational supplies.
Training the people who will perform the work
The investigator must understand and oversee the trial, and staff need training appropriate to their responsibilities before performing those activities. Attendance at one entire meeting by every named person is not a universal ICH rule. The sponsor may require PI attendance under its initiation procedure; apply that requirement accurately.
If the PI is unavailable, staff training or readiness review may still proceed under an appropriate plan. Do not declare the site ready until required investigator training and critical readiness conditions are satisfied and documented. Arrange remote or separate training where appropriate, retain evidence and confirm understanding. Distinguish meeting completion from authorisation to screen, enrol, dispense or dose.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E8(R1).
A site has finished a training meeting but lacks required approval for enrolment. What does meeting completion permit?
Immediate dosing of the first available patient.
Retroactive approval of all activity.
A monitor’s verbal waiver of ethics review.
It does not itself authorise enrolment; verify the required decision and readiness conditions.
Sections you finish are checked off in the contents.